Article Text

Download PDFPDF
LDL cholesterol response to statins and future risk of cardiovascular disease
  1. Ralph Kwame Akyea,
  2. Joe Kai,
  3. Nadeem Qureshi,
  4. Barbara Iyen,
  5. Stephen F Weng
  1. Division of Primary Care, University of Nottingham, Nottingham, Nottinghamshire, UK
  1. Correspondence to Dr Stephen F Weng, Division of Primary Care, University of Nottingham, Nottingham NG7 2RD, UK; stephen.weng{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

To the Editor

Our recently published study using electronic health records from primary care setting in the UK examined low-density lipoprotein cholesterol (LDL-C) reduction among patients initiating statins.1 We are grateful to Dr Taher Modarressi, Dr Dieter Lütjohann, Professor Oliver Weingärtner, Dr Tülin Muggleton and Dr Ellis Muggleton for their comments.

With regards to the points raised:

Suboptimal cholesterol response to initiation of statins and future risk of cardiovascular disease – Dr Taher Modarressi

While biomarkers are useful to establish associations with various disease conditions including cardiovascular disease (CVD), often these biomarkers are not routinely offered or measured in primary care settings within the UK, and hence are not available in electronic health records. Lipoprotein(a) (Lp(a)), a large lipoprotein particle produced in the liver, is not routinely measured in patients in UK general practice. There is, however, evidence indicating Lp(a) might be a useful biomarker that has …

View Full Text


  • RKA and SFW contributed equally.

  • Contributors SFW is guarantor.

  • Funding The research was funded and supported by the University of Nottingham.

  • Competing interests NQ is a member of the National Institute for Health and Care Excellence (NICE) Familial Hypercholesterolaemia Guideline Development Group (CG71) and NICE Lipid Modification Guidelines Group (CG181). SFW is a member of the Clinical Practice Research Datalink Independent Scientific Advisory Committee and previously held an National Institute for Health Research - School for Primary Care Research (NIHR-SPCR) career launching fellowship award. The remaining authors have no competing interests.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Linked Articles